Navigation Links
Chem Rx Corporation Schedules 2008 Annual Meeting Date

LONG BEACH, N.Y., Oct. 31 /PRNewswire-FirstCall/ -- Chem Rx Corporation (OTC Bulletin Board: CHRX, CHRXU, CHRXW), a leading provider of institutional pharmacy services, today announced that its 2008 annual meeting of stockholders is planned to be held on Thursday, December 18, 2008. The meeting is scheduled for 10:00 a.m. local time at the offices of Paramount BioSciences, LLC, located at 787 Seventh Avenue, 48th Floor, New York, New York 10019. Stockholders of record as of the close of business on November 3, 2008 will be entitled to vote at the meeting or any adjournment of the meeting. Any stockholder that intends to present a proposal for inclusion in the Company's proxy materials for the 2008 Annual Meeting must submit the proposal, in accordance with Securities Exchange Act of 1934 Rule 14a-8, not later than the close of business on Thursday, November 20, 2008.

About Chem Rx Corporation

Founded more than 40 years ago, Chem Rx Corporation is a leading provider of institutional pharmacy services in the New York City metropolitan area, as well as parts of New Jersey, upstate New York, Pennsylvania, and Florida. Chem Rx's client base includes skilled nursing facilities and a wide range of other long-term care facilities. Through its services, Chem Rx provides more than 67,500 institutional residents with prescription and non-prescription drugs, intravenous medications, durable medical equipment items and surgical supplies. Chem Rx's website address is

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are based upon the current beliefs and expectations of Chem Rx's management and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: compliance with government regulations; changes in legislation or regulatory environments; requirements or changes adversely affecting the health care industry, including changes in Medicare reimbursement policies; fluctuations in customer demand; management of rapid growth; intensity of competition; timing, approval and market acceptance of new product introductions and institutional pharmacy locations; general economic conditions; geopolitical events and regulatory changes, as well as other relevant risks detailed in Chem Rx's filings with the Securities and Exchange Commission. The information set forth herein should be read in light of such risks. Chem Rx Corporation does not assume any obligation to update the information contained in this press release.


Steven C. Silva

President and Chief Operating Officer

Chem Rx Corporation


Stephanie Carrington/Ben Carmichael

The Ruth Group

646-536-7017 / 7013

SOURCE Chem Rx Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Torchmark Corporation Declares Dividend
2. Baxa Corporation Launches The Virtual Compounder(TM)
3. MedCath Corporation to Hold Conference Call on Fourth Quarter Results
4. HLTH Corporation Announces Third Quarter Financial Results
5. Alsius Corporation to Host Third Quarter 2008 Financial Results Conference Call on November 6
6. Deloitte Names Heska Corporation to Colorado Technology Fast 50
7. AMERIGROUP Corporation to Present at the 17th Annual Credit Suisse Healthcare Conference on November 13
8. Webcast Alert: Air Methods Corporation Announces Third Quarter 2008 Financial Results
9. Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million
10. The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future
11. Berger & Montague Announces Class Action Lawsuit Against Elan Corporation
Post Your Comments:
(Date:12/1/2015)... ... 2015 , ... CloudLIMS today announced that it is the ... the New Products and Services category for its innovative product offering, BioTracer. ... that helps labs organize data and track samples with storage inventories. BioTracer's SaaS ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... must mark the film for accurate interpretation by the radiologist. The marking utensils ... inventor from Sacramento, Calif., has found a way to alleviate this problem. , ...
(Date:12/1/2015)... ... 2015 , ... McLean, VA., December 1, 2015 - Octo ... sprint agile development contract to support the National Geospatial-Intelligence Agency's (NGA) IT Services ... engineering, infrastructure, as well as operations and sustainment support to the NGA’s Agile ...
(Date:12/1/2015)... GA (PRWEB) , ... December 01, 2015 , ... ... supports SACC-GA and SACC-USA through membership and leadership since 2008. Gary ... Chair for SACC-USA . Gary has spent a significant amount of time ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation recognizes Tympani as ... Cisco Unified Contact Center solutions targeted to the high-end enterprise contact center marketplace. ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015 Russia has always ... 70% of new drugs registered in Europe in ... --> Russia has always been a country ... drugs registered in Europe in 2015 were tested ... Russia has always been a country of choice ...
(Date:12/1/2015)... Dec. 1, 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... chronic pain, announced today that the company will present at ... December 1-3 at the Luxe Sunset Boulevard Hotel in ... CEO of Relmada Therapeutics, will present on Thursday, December 3, ... . Please register at least 10 minutes prior ...
(Date:12/1/2015)...   MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), ... filed an Investigational New Drug Application (IND) with the ... lead fully human antibody product HuMab 5B1 as a ... initiate the Phase I clinical trial early in 2016. ... The planned Phase I trial will evaluate the safety, ...
Breaking Medicine Technology: